Melola Discovery

← Melola Discovery

Akses terbuka Jurnal SINTA 1

Profile of MIBI Liquid Phase Radiopharmaceutical for Myocardial Imaging

Atom Indonesia · Vol. 42 No. 1 (2016) · hlm. 27–32

DOI
10.17146/aij.2016.476
ISSN
2356-5322, 0126-1568
Terbit
2016-04-06
Penerbit
National Research and Innovation Agency
Bahasa
eng
Lisensi
creativecommons.org/licenses/by-nc-sa/4.0

Abstrak

The 99mTc-MIBI radiopharmaceutical has been used innuclear medicine in Indonesia for myocardial imaging. BATAN researchers have mastered the technology to manufacture MIBI as a liophylized kit. A reformulation of MIBI radiopharmaceutical has been conducted to improve the stability of the kit especially in the liquid-phase kit. Basically, radiopharmaceuticals in liquid form are not different from the dry kit. However in the manufacturing of liquid-phase kit, lyophilization process was not done. To improve the stability of liquid kit, a reformulation of the components was conducted by using two separate vials (Formulation 2) and the characteristics were compared with the one-vial formulation (Formulation 1). The MIBI Formulation 2 consists of two vials, vial A containing 0.06 mg of SnCl2 2H2O and 2.6 mg Sodium Citrate 2H2O and vial B containing 0.5 mg of [Cu(MIBI)4]BF4, 1 mg of cysteine hydrochloride, and 20 mg of mannitol.The purposes of this study wereto determine the stability of two different formulations of MIBI as a liquid-phase kit, to compare their stability in different storage condition such as in refrigerator and freezer, and to compare the ratio of activities attained between target and nontarget organs after injection to animal model. As a diagnostic agent, MIBI was reconstituted with Technetium-99m as radionuclide tracer to 99mTc-MIBI labeled compound. The radiochemical purity of 99mTc-MIBI was determined by chromatography method using alumina thin-layer chromatography paper as the stationary phase and ethanol 95% as the mobile phase. The results showed MIBI Formulation 2 has a higher stability than Formulation 1. Formulation 2 also maintained a 96.68% radiochemical purity under 52-day storage and attained a target-to-nontarget activity ratio of 8.22.Received: 04 October 2014; Revised: 10 November 2015; Accepted: 25 November 2015

Kata kunci

Jaringan kolaborasi para penulis

29 penulis · 85 tautan kepenulisan bersama · 39 lintas organisasi

Arahkan kursor atau ketuk sebuah nama untuk menyorot rekan penulisnya. Klik dua kali untuk membuka halaman penulis.

  • National Nuclear Energy Agency of Indonesia
  • Universitas Bakti Tunas Husada
  • Universitas Jenderal Achmad Yani
  • Sekolah Tinggi Farmasi Indonesia
  • Bandung Institute of Technology
  • Nuclear Energy Agency
  • Padjadjaran University
  • Afiliasi tidak diketahui
  • Organisasi berbeda
  • Organisasi sama
  • Afiliasi tidak diketahui
  • Garis lebih tebal = lebih banyak artikel bersama · lingkaran lebih besar = lebih banyak artikel
Tampilkan sebagai tabel
Rekan penulisOrganisasiArtikel bersama
Eva Maria WidyasariNational Nuclear Energy Agency of Indonesia5
Witri NuraeniNational Nuclear Energy Agency of Indonesia3
I. MahendraAfiliasi tidak diketahui2
Rizky Juwita SugihartiNational Nuclear Energy Agency of Indonesia2
D. SetiawanAfiliasi tidak diketahui2
Teguh Hafiz Ambar WibawaNational Nuclear Energy Agency of Indonesia1
Iim HalimahNational Nuclear Energy Agency of Indonesia1
S. R. PajrinSekolah Tinggi Farmasi Indonesia1
T. H. AmbarwibawaNuclear Energy Agency1
Z NurlailaNational Nuclear Energy Agency of Indonesia1
Heni RachmawatiBandung Institute of Technology1
Aang Hanafiah WangsaatmadjaNational Nuclear Energy Agency of Indonesia1
DEBBIE SOEFIE RETNONINGRUMBandung Institute of Technology1
Esty KusumawardhanyAfiliasi tidak diketahui1
Muharam MarzukiAfiliasi tidak diketahui1
Veronika Yulianti SusiloNational Nuclear Energy Agency of Indonesia1
Ruswanto RuswantoUniversitas Bakti Tunas Husada1
Anindita Tri Kusuma PratitaUniversitas Bakti Tunas Husada1
Febby PratamaUniversitas Bakti Tunas Husada1
Tita NofiantiUniversitas Bakti Tunas Husada1
Holis Abdul HolikPadjadjaran University1
Dian Ayu UtamiUniversitas Jenderal Achmad Yani1
Mega Susilo DwikeUniversitas Jenderal Achmad Yani1
Muharram MarzukiUniversitas Jenderal Achmad Yani1

Afiliasi berasal dari OpenAlex; metadata OAI-PMH jurnal tidak memuatnya. Penulis tanpa ID OpenAlex dicocokkan berdasarkan nama, sehingga dua orang bisa tergabung atau satu orang bisa terpisah.

Sumber metadata: OAI-PMH (metadata jurnal) https://atomindonesia.brin.go.id/index.php/aij/oai, pertama di-harvest 8 Nov 2026, terakhir terlihat 16 Nov 2026.
Metadata asli (oai_dc)
<oai_dc:dc xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/  http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en-US">Profile of MIBI Liquid Phase Radiopharmaceutical for Myocardial Imaging</dc:title>
	<dc:creator>Daruwati, I.</dc:creator>
	<dc:creator>Sriyani, M.E.</dc:creator>
	<dc:creator>Oekar, N.K.</dc:creator>
	<dc:creator>Hanafiah, A.</dc:creator>
	<dc:creator>Zainuddin, N.</dc:creator>
	<dc:subject xml:lang="en-US">99mTc-MIBI; Stability of Liquid Phase Kit; Myocardial Imaging</dc:subject>
	<dc:description xml:lang="en-US">The 99mTc-MIBI radiopharmaceutical has been used innuclear medicine in Indonesia for myocardial imaging. BATAN researchers have mastered the technology to manufacture MIBI as a liophylized kit. A reformulation of MIBI radiopharmaceutical has been conducted to improve the stability of the kit especially in the liquid-phase kit. Basically, radiopharmaceuticals in liquid form are not different from the dry kit. However in the manufacturing of liquid-phase kit, lyophilization process was not done. To improve the stability of liquid kit, a reformulation of the components was conducted by using two separate vials (Formulation 2) and the characteristics were compared with the one-vial formulation (Formulation 1). The MIBI Formulation 2 consists of two vials, vial A containing 0.06 mg of SnCl2 2H2O and 2.6 mg Sodium Citrate 2H2O and vial B containing 0.5 mg of [Cu(MIBI)4]BF4, 1 mg of cysteine hydrochloride, and 20 mg of mannitol.The purposes of this study wereto determine the stability of two different formulations of MIBI as a liquid-phase kit, to compare their stability in different storage condition such as in refrigerator and freezer, and to compare the ratio of activities attained between target and nontarget organs after injection to animal model. As a diagnostic agent, MIBI was reconstituted with Technetium-99m as radionuclide tracer to 99mTc-MIBI labeled compound. The radiochemical purity of 99mTc-MIBI was determined by chromatography method using alumina thin-layer chromatography paper as the stationary phase and ethanol 95% as the mobile phase. The results showed MIBI Formulation 2 has a higher stability than Formulation 1. Formulation 2 also maintained a 96.68% radiochemical purity under 52-day storage and attained a target-to-nontarget activity ratio of 8.22.Received: 04 October 2014; Revised: 10 November 2015; Accepted: 25 November 2015</dc:description>
	<dc:publisher xml:lang="en-US">National Research and Innovation Agency</dc:publisher>
	<dc:contributor xml:lang="en-US">National Nuclear Energy Agency of Indonesia</dc:contributor>
	<dc:date>2016-04-06</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en-US"></dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://atomindonesia.brin.go.id/index.php/aij/article/view/476</dc:identifier>
	<dc:identifier>10.17146/aij.2016.476</dc:identifier>
	<dc:source xml:lang="en-US">Atom Indonesia; Vol 42, No 1 (2016): April 2016; 27 - 32</dc:source>
	<dc:source>2356-5322</dc:source>
	<dc:source>0126-1568</dc:source>
	<dc:source>10.55981/aij.v42i1</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://atomindonesia.brin.go.id/index.php/aij/article/view/476/368</dc:relation>
	<dc:relation>https://atomindonesia.brin.go.id/index.php/aij/article/downloadSuppFile/476/317</dc:relation>
	<dc:relation>https://atomindonesia.brin.go.id/index.php/aij/article/downloadSuppFile/476/471</dc:relation>
	<dc:relation>https://atomindonesia.brin.go.id/index.php/aij/article/downloadSuppFile/476/318</dc:relation>
	<dc:relation>https://atomindonesia.brin.go.id/index.php/aij/article/downloadSuppFile/476/473</dc:relation>
	<dc:relation>https://atomindonesia.brin.go.id/index.php/aij/article/downloadSuppFile/476/475</dc:relation>
	<dc:relation>https://atomindonesia.brin.go.id/index.php/aij/article/downloadSuppFile/476/481</dc:relation>
	<dc:relation>https://atomindonesia.brin.go.id/index.php/aij/article/downloadSuppFile/476/482</dc:relation>
	<dc:relation>https://atomindonesia.brin.go.id/index.php/aij/article/downloadSuppFile/476/320</dc:relation>
	<dc:relation>https://atomindonesia.brin.go.id/index.php/aij/article/downloadSuppFile/476/319</dc:relation>
	<dc:relation>https://atomindonesia.brin.go.id/index.php/aij/article/downloadSuppFile/476/321</dc:relation>
	<dc:rights xml:lang="en-US">Copyright (c) 2016 Atom Indonesia</dc:rights>
	<dc:rights xml:lang="en-US">http://creativecommons.org/licenses/by-nc-sa/4.0</dc:rights>
</oai_dc:dc>